{"id":"NCT05007392","sponsor":"Eisai Co., Ltd.","briefTitle":"A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout","officialTitle":"A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-21","primaryCompletion":"2023-06-14","completion":"2023-06-14","firstPosted":"2021-08-16","resultsPosted":"2025-07-30","lastUpdate":"2025-07-30"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"Dotinurad","otherNames":["FYU-981"]},{"type":"DRUG","name":"Febuxostat","otherNames":[]},{"type":"OTHER","name":"Dotinurad Matched Placebo","otherNames":[]},{"type":"OTHER","name":"Febuxostat Matched Placebo","otherNames":[]}],"arms":[{"label":"Drug: Dotinurad + Febuxostat Matched Placebo","type":"EXPERIMENTAL"},{"label":"Drug: Febuxostat + Dotinurad Matched Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level less than or equal to (\\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese participants with gout.","primaryOutcome":{"measure":"Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)","timeFrame":"At Week 24","effectByArm":[{"arm":"Febuxostat","deltaMin":38.1,"sd":null},{"arm":"Dotinurad","deltaMin":73.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":225},"commonTop":["Gouty arthritis","COVID-19","Alanine aminotransferase increased","Hepatic function abnormal","Upper respiratory tract infection"]}}